 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHI Advisors LLC grew its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR  Free Report) by 24.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The...

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is CHI Advisors LLC's 8th Largest Position

This indicator may be signaling that LRMR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Larimar Therapeutics (LRMR, $3.09) entered Downtrend as Momentum indicator drops below 0 level on Nov 21, 2023

This is a signal that LRMR's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Larimar Therapeutics (LRMR, $3.29) Stochastic Oscillator left the overbought zone on November 17, 2023

For the last three days, A.I.dvisor has detected that LRMR's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Larimar Therapeutics (LRMR, $3.09) Aroon Indicator entered a Downtrend on November 16, 2023.

Larimar Therapeutics GAAP EPS of -$0.21 beats by $0.02...

Larimar Therapeutics GAAP EPS of -$0.21 beats by $0.02

Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious...

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Larimar Therapeutics (LRMR, $3.1) Aroon Indicator entered a Downtrend on November 06, 2023.

BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ( Larimar ) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Larimar Therapeutics: Underweight Cash Burners In More Niche Markets...

Larimar Therapeutics: Underweight Cash Burners In More Niche Markets

This is a signal that LRMR's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Larimar Therapeutics (LRMR, $3.14) Stochastic Oscillator left the oversold zone on October 17, 2023

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Watchers	3,741
52-Wk Low	$2.18
52-Wk High	$6.85

Market Cap	$157.53M
Volume (M)	70,420.00
52-Wk High	$6.85
52-Wk Low	$2.18

Period	Estimated	Reported	Surprise	Result
Q3'23	$-0.22	$-0.21	6.02%	BEAT
Q2'23	$-0.19	$-0.19	2.55%	BEAT
Q1'23	$-0.25	$-0.15	39.57%	BEAT
Q4'22	$-0.37	$-0.21	43.86%	BEAT
Q3'22	$-0.42	$-0.37	11.90%	BEAT

LRMR Larimar Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals